Stock comparison
Genmab A/S
Medpace Holdings
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
GMAB
Genmab A/S
Market cap
$16.5B
Sector
Healthcare
MEDP
Medpace Holdings
Market cap
$12.36B
Sector
Healthcare
Overall winner
Medpace Holdings MEDP
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | GMAB | MEDP | Winner |
|---|---|---|---|
| Warren Buffett | 65C | 61C | GMAB |
| Benjamin Graham | 64C | 67B | MEDP |
| Philip Fisher | 48D | 70B | MEDP |
| Peter Lynch | 25F | 65B | MEDP |
| Joel Greenblatt | 76B | 79B | MEDP |
| Charlie Munger | 68C | 67B | GMAB |
| Terry Smith | 71C | 75B | MEDP |
Side-by-side metrics
| Metric | GMAB | MEDP |
|---|---|---|
| Market cap | $16.5B | $12.36B |
| P/E (TTM) | 6.2x | 25.7x |
| EV/EBIT | 12.0x | 21.2x |
| ROIC (TTM) | 43.78% | 56.06% |
| Gross margin | 93.88% | 29.07% |
| Net margin | 18.23% | 17.19% |
| Revenue CAGR 5y | -18.45% | 21.99% |
| EPS CAGR 5y | -23.48% | 32.59% |
| Debt / Equity | 0.1x | 0.2x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
GMAB leads on
- P/E (TTM)6.2xvs 25.7x+76%
- Debt / Equity0.1xvs 0.2x+70%
- Gross margin93.88%vs 29.07%+69%
- EV/EBIT12.0xvs 21.2x+44%
MEDP leads on
- Revenue CAGR 5y21.99%vs -18.45%+184%
- EPS CAGR 5y32.59%vs -23.48%+172%
- ROIC (TTM)56.06%vs 43.78%+22%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.